2-Benzyl-4-[4'-(2-benzylbenzofuran-3-yl)biphen-4-yl]-4-oxobutyric acid | 796033-13-1

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 2-Benzyl-4-[4'-(2-benzylbenzofuran-3-yl)biphen-4-yl]-4-oxobutyric acid
• 英文别名: 2-benzyl-4-[4-[4-(2-benzyl-1-benzofuran-3-yl)phenyl]phenyl]-4-oxobutanoic acid
• CAS: 796033-13-1
• 化学式: C₃₈H₃₀O₄
• 分子量: 550.654
• InChiKey: NQDPPXMOGTWHAA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.6
• 重原子数：
  42
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  67.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-benzyl-5-{2-[4'-(2-benzylbenzofuran-3-yl)-biphen-4-yl]-2-oxoethyl}-2,2-dimethyl-[1,3]dioxane-4,6-dione 在 盐酸 作用下， 以 四氢呋喃 、 二甲基亚砜 为溶剂， 反应 9.0h， 生成 2-Benzyl-4-[4'-(2-benzylbenzofuran-3-yl)biphen-4-yl]-4-oxobutyric acid
  参考文献：
  名称：

  Substituted carboxylic acids

  摘要：

  本发明涉及公式I的化合物和药用盐，这些化合物在治疗与胰岛素抵抗或高血糖相关的代谢紊乱方面具有用处。这些化合物包括蛋白酪氨酸磷酸酶（PTP-1B）的抑制剂，对于糖尿病和其他PTP-1B介导的疾病（如癌症、神经退行性疾病等）的治疗具有用处。本发明的化合物还可用于制备药物组合物和治疗上述疾病的方法。

  公开号：

  US20060094747A1

文献信息

• [EN] CONTINUOUS ARYCYCLIC COMPOUND<br/>[FR] COMPOSÉ ARYCYCLIQUE CONTINU
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2012081736A1

  公开（公告）日：2012-06-21

  This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.

  这是为了提供一种具有DGAT1抑制活性的连续芳环化合物，用于预防和/或治疗由肥胖引起的肥胖或高脂血症、高三酸甘油酯血症、脂质代谢紊乱、脂肪肝、高血压、动脉硬化、糖尿病等，以及提供包含所述连续芳环化合物或其药学上可接受的盐的DGAT1抑制剂作为有效成分。所述连续芳环化合物由以下式表示：其中式中的取代基与规范中定义的相同，或其药学上可接受的盐。
• Substituted Carboxylic Acids
  申请人：Van Zandt Michael C.

  公开号：US20090082392A1

  公开（公告）日：2009-03-26

  The present invention relates to compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention are also useful in pharmaceutical compositions and methods of treating the aforementioned conditions.

  本发明涉及公式（I）化合物及其药学上可接受的盐，用于治疗与胰岛素抵抗或高血糖有关的代谢性疾病。这些化合物包括蛋白酪氨酸磷酸酶（PTP-1B）的抑制剂，可用于治疗糖尿病和其他PTP-1B介导的疾病，如癌症、神经退行性疾病等。本发明的化合物也适用于制药组合物和治疗上述疾病的方法。
• CONTINUOUS ARYCYCLIC COMPOUND
  申请人：Sakurai Osamu

  公开号：US20130261128A1

  公开（公告）日：2013-10-03

  This is to provide a continuous arycyclic compound having a DGAT1 inhibitory activity, and useful for prophylaxis and/or treatment of obesity or hyperlipidemia caused by obesity, hypertriglyceridemia, lipid metabolism disorder, fatty liver, hypertension, arteriosclerosis, diabetes, etc., as well as to provide a DGAT1 inhibitor comprising the continuous arycyclic compound or a pharmaceutically acceptable salt thereof as an effective ingredient. Disclosed is the continuous arycyclic compound is represented by the formula: wherein the substituents in the formula are the same as defined in the specification, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种具有DGAT1抑制活性的连续芳环化合物，可用于预防和/或治疗由肥胖、高甘油三酯血症、脂质代谢紊乱、脂肪肝、高血压、动脉硬化、糖尿病等引起的肥胖或高脂血症，同时提供了一种包含连续芳环化合物或其药学上可接受的盐作为有效成分的DGAT1抑制剂。所披露的连续芳环化合物由以下公式表示：其中公式中的取代基与说明书中定义的相同，或其药学上可接受的盐。
• AROMATIC HETEROCYCLIC COMPOUND
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2862856A1

  公开（公告）日：2015-04-22

  The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

  由通式表示的化合物：其中环 A 是苯，可被取代等；环 B 是苯，可被取代等；X 是单键等；Y 是烷基，可被取代等；Z 是 CR1 或氮原子；R1 是氢等；R2 是烷基，可被取代等或其药学上可接受的盐，可用作肥胖症、糖尿病等的预防/治疗剂。
• Aromatic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10308636B2

  公开（公告）日：2019-06-04

  The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

  由通式表示的化合物：其中环 A 是苯，可被取代等；环 B 是苯，可被取代等；X 是单键等；Y 是烷基，可被取代等；Z 是 CR1 或氮原子；R1 是氢等；R2 是烷基，可被取代等或其药学上可接受的盐，可用作肥胖症、糖尿病等的预防/治疗剂。